SPARC gets USFDA nod for SEZABY for the remedy of Neonatal Seizures by admin- Friday, November 18th, 2022 04:20:44 PM
Sun Pharmaceutical Industries and and Sun Pharma Advanced Research Company announced that the United States Food and Drug Administration (USFDA) has permitted SEZABY (phenobarbital sodium powder for injection) for the treatment of neonatal seizures.
With this approval, SEZABY turns into the primary and best product particularly indicated in the US for the treatment of neonatal seizures in term and preterm toddlers. SEZABY is predicted to be available in the US in Q4FY23.
SEZABY is a benzyl alcohol-loose and propylene glycol-loose formula of phenobarbital sodium powder for injection. It changed into granted orphan drug designation through the United States FDA for the remedy of neonatal seizures.